Trial Profile
An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumours (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Golvatinib (Primary) ; Lenvatinib (Primary)
- Indications Glioblastoma; Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 12 May 2021 Status changed from completed to discontinued.
- 05 Mar 2020 Status changed from active, no longer recruiting to completed.
- 02 Jun 2016 Planned End Date changed to 1 Dec 2016.